Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Tarlatamab

Review the clinical trials studying tarlatamab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-10 of 10

Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
Status: Active
Location: 13 locations
Tarlatamab for the Treatment of DLL3 Positive Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer, The TIDAL Trial
Status: Active
Location: 7 locations
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
Status: Active
Location: 5 locations
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Status: Active
Location: 5 locations
Tarlatamab for the Treatment of DLL3-Expressing Stage III or IV Neuroendocrine Neoplasms and Other Solid Tumors
Status: Active
Location: 4 locations
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Tarlatamab in Combination with Standard of Care Radiation Therapy for the Treatment of Relapsed or Refractory of DLL3-Expressing Small Cell Lung Cancers and other High Grade Neuroendocrine Cancers
Status: Active
Location: Banner University Medical Center - Tucson, Tucson, Arizona
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Status: Active
Location: See ClinicalTrials.gov
A Study of Hospital-at-Home for People Receiving Tarlatamab, MATCHES-Novel Trial
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Status: Active
Location: 2 locations